Plasma Prostaglandin E2 Metabolite Levels Predict Type 2 Diabetes Status and One-Year Therapeutic Response Independent of Clinical Markers of Inflammation
暂无分享,去创建一个
D. Davis | M. Kimple | Allison L. Brill | Samantha Pabich | D. Peter | Alice M. Weeks | Randall Nall | Margaret Punt | Elizabeth D. Cox | Rachel J. Fenske | Michael Daniels
[1] F. Ginhoux,et al. Role of adipose tissue macrophages in obesity-related disorders , 2022, The Journal of experimental medicine.
[2] M. Gannon,et al. Effects of Arachidonic Acid and Its Metabolites on Functional Beta-Cell Mass , 2022, Metabolites.
[3] B. Berthon,et al. Weight Loss and Short-Chain Fatty Acids Reduce Systemic Inflammation in Monocytes and Adipose Tissue Macrophages from Obese Subjects , 2022, Nutrients.
[4] R. Kukreti,et al. Mechanistic Insight into Oxidative Stress-Triggered Signaling Pathways and Type 2 Diabetes , 2022, Molecules.
[5] R. Breyer,et al. Pharmacological blockade of the EP3 prostaglandin E2 receptor in the setting of type 2 diabetes enhances β-cell proliferation and identity and relieves oxidative damage , 2021, Molecular metabolism.
[6] D. Davis,et al. Human Islet Expression Levels of Prostaglandin E2 Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity. , 2021, ACS Pharmacology & Translational Science.
[7] Ling Geng,et al. Comparison of the triglyceride glucose index and blood leukocyte indices as predictors of metabolic syndrome in healthy Chinese population , 2021, Scientific Reports.
[8] Yongman Lv,et al. The role of systemic inflammation in the association between serum 25-hydroxyvitamin D and type 2 diabetes mellitus. , 2021, Clinical nutrition.
[9] R. Breyer,et al. Rat prostaglandin EP3 receptor is highly promiscuous and is the sole prostanoid receptor family member that regulates INS‐1 (832/3) cell glucose‐stimulated insulin secretion , 2021, Pharmacology research & perspectives.
[10] Dudley Lamming,et al. Systemic Metabolic Alterations Correlate with Islet-Level Prostaglandin E2 Production and Signaling Mechanisms That Predict β-Cell Dysfunction in a Mouse Model of Type 2 Diabetes , 2021, Metabolites.
[11] Kathryn A Carbajal,et al. Agonist-independent Gαz activity negatively regulates beta-cell compensation in a diet-induced obesity model of type 2 diabetes , 2020, The Journal of biological chemistry.
[12] A. Barsch,et al. Ultrahigh-Resolution Mass Spectrometry-Based Platform for Plasma Metabolomics Applied to Type 2 Diabetes Research. , 2020, Journal of proteome research.
[13] J. Wan,et al. Quantitative profiling of eicosanoids derived from n-6 and n-3 polyunsaturated fatty acids by twin derivatization strategy combined with LC-MS/MS in patients with type 2 diabetes mellitus. , 2020, Analytica chimica acta.
[14] R. Wevers,et al. Evaluation of cyclooxygenase oxylipins as potential biomarker for obesity-associated adipose tissue inflammation and type 2 diabetes using targeted multiple reaction monitoring mass spectrometry. , 2020, Prostaglandins, leukotrienes, and essential fatty acids.
[15] Minjoo Kim,et al. Inflammatory Markers and Plasma Fatty Acids in Predicting WBC Level Alterations in Association With Glucose-Related Markers: A Cross-Sectional Study , 2020, Frontiers in Immunology.
[16] A. Sikalidis,et al. The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing A Complex Relationship , 2020, Biomedicines.
[17] A. Das,et al. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D). , 2019, The Journal of the Association of Physicians of India.
[18] X. Hou,et al. Serum Metrnl Level is Correlated with Insulin Resistance, But Not with β-Cell Function in Type 2 Diabetics , 2019, Medical science monitor : international medical journal of experimental and clinical research.
[19] B. Thorens,et al. Use of preclinical models to identify markers of type 2 diabetes susceptibility and novel regulators of insulin secretion – A step towards precision medicine , 2019, Molecular metabolism.
[20] P. Jakobsson,et al. Urinary prostaglandin D2 and E2 metabolites associate with abdominal obesity, glucose metabolism, and triglycerides in obese subjects. , 2019, Prostaglandins & other lipid mediators.
[21] G. Rogers,et al. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release , 2019, Front. Physiol..
[22] D. Eizirik,et al. Biomarkers of islet beta cell stress and death in type 1 diabetes , 2018, Diabetologia.
[23] L. Groop,et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.
[24] I. Harsch,et al. The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases , 2018, Medical sciences.
[25] J. Nessler,et al. Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease , 2018, Cardiovascular Diabetology.
[26] N. Inagaki,et al. Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis , 2017, Journal of diabetes investigation.
[27] K. Sung,et al. Inflammation in the Prediction of Type 2 Diabetes and Hypertension in Healthy Adults. , 2017, Archives of medical research.
[28] M. Kimple,et al. The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease , 2017, The AAPS Journal.
[29] Kathryn A Carbajal,et al. The Inhibitory G Protein &agr;-Subunit, G&agr;z, Promotes Type 1 Diabetes-Like Pathophysiology in NOD Mice , 2017, Endocrinology.
[30] R. Robertson,et al. The COX-2/PGE2/EP3/Gi/o/cAMP/GSIS Pathway in the Islet: The Beat Goes On , 2017, Diabetes.
[31] Bethany A. Carboneau,et al. Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human β-cell survival and proliferation , 2017, Molecular metabolism.
[32] K. Eliceiri,et al. Enriching Islet Phospholipids With Eicosapentaenoic Acid Reduces Prostaglandin E2 Signaling and Enhances Diabetic β-Cell Function , 2017, Diabetes.
[33] A. Owora. Diagnostic Validity and Clinical Utility of HbA1C Tests for Type 2 Diabetes Mellitus , 2016, Current diabetes reviews.
[34] R. Mirmira,et al. Biomarkers of β-Cell Stress and Death in Type 1 Diabetes , 2016, Current Diabetes Reports.
[35] A. Scheen. Precision medicine: The future in diabetes care? , 2016, Diabetes research and clinical practice.
[36] M. Kimple,et al. Dietary polyunsaturated fatty acids and their metabolites: Implications for diabetes pathophysiology, prevention, and treatment , 2016, Nutrition and healthy aging.
[37] M. Kimple,et al. Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes. , 2016, Molecular endocrinology.
[38] Allan Vaag,et al. Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes , 2016, Nature Communications.
[39] Sher Ali,et al. Genes, Genetics, and Environment in Type 2 Diabetes: Implication in Personalized Medicine. , 2016, DNA and cell biology.
[40] 2. Classification and Diagnosis of Diabetes , 2014, Diabetes Care.
[41] G. Sesti,et al. Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria , 2015, Acta Diabetologica.
[42] A. Piwowar,et al. [Associations between basic indicators of inflammation and metabolic disturbances]. , 2014, Postepy higieny i medycyny doswiadczalnej.
[43] D. Juárez,et al. Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication. , 2014, Population health management.
[44] V. Mohan,et al. Association of neutrophil-lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. , 2014, Diabetes technology & therapeutics.
[45] P. Casey,et al. Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes , 2014, Experimental & Molecular Medicine.
[46] M. Nieuwdorp,et al. Role of the microbiome in energy regulation and metabolism. , 2014, Gastroenterology.
[47] F. Welty. How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis? , 2013, Current Cardiology Reports.
[48] M. Kimple,et al. The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics. , 2013, Journal of endocrinology, diabetes & obesity.
[49] A. Attie,et al. Prostaglandin E2 Receptor, EP3, Is Induced in Diabetic Islets and Negatively Regulates Glucose- and Hormone-Stimulated Insulin Secretion , 2013, Diabetes.
[50] M. Carnero,et al. Relationship between serum levels of triglycerides and vascular inflammation, measured as COX-2, in arteries from diabetic patients: a translational study , 2013, Lipids in Health and Disease.
[51] L. Makowski,et al. The inflammation highway: metabolism accelerates inflammatory traffic in obesity , 2012, Immunological reviews.
[52] R. Robertson,et al. Cyclooxygenase-2, Not Microsomal Prostaglandin E Synthase-1, Is the Mechanism for Interleukin-1β-induced Prostaglandin E2 Production and Inhibition of Insulin Secretion in Pancreatic Islets* , 2012, The Journal of Biological Chemistry.
[53] P. Casey,et al. Deletion of GαZ Protein Protects against Diet-induced Glucose Intolerance via Expansion of β-Cell Mass* , 2012, The Journal of Biological Chemistry.
[54] Shih-Yi Lin,et al. Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies , 2010, PloS one.
[55] D. Drucker,et al. Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.
[56] A. Syrenicz,et al. Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. , 2006, Neuro endocrinology letters.
[57] P. Casey,et al. A Role for Gz in Pancreatic Islet β-Cell Biology* , 2005, Journal of Biological Chemistry.
[58] W. März,et al. Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study , 2004, Circulation.
[59] J. Vane,et al. The mechanism of action of aspirin. , 2003, Thrombosis research.
[60] R. Robertson,et al. Inhibition of Interleukin-1β-Induced COX-2 and EP3 Gene Expression by Sodium Salicylate Enhances Pancreatic Islet β-Cell Function , 2002 .
[61] Christian Weyer,et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.
[62] R. Robertson,et al. Prostaglandin E2 Mediates Inhibition of Insulin Secretion by Interleukin-1β* , 1999, The Journal of Biological Chemistry.
[63] R. Robertson,et al. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. , 1998, Diabetes.
[64] Å. Sjöholm,et al. Prostaglandins inhibit pancreatic beta-cell replication and long-term insulin secretion by pertussis toxin-insensitive mechanisms but do not mediate the actions of interleukin-1 beta. , 1996, Biochimica et biophysica acta.
[65] S. Bonakdaran,et al. Correlation Between White Blood Cell Count and Insulin Resistance in Type 2 Diabetes. , 2018, Current diabetes reviews.
[66] BOULIN,et al. Classification and Diagnosis of Diabetes. , 2022, Primary care.
[67] T. Forst,et al. A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus. , 2008, Clinical Laboratory.
[68] J. Chan,et al. White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes. , 2004, Diabetes care.